Gilead Anticipates Lucrative Atripla Launch In EU, Maintains Optimism About Letairis
This article was originally published in The Pink Sheet Daily
Executive Summary
Detailing its fourth-quarter and full-year 2007 financials, Gilead predicts nine-month rollout for Atripla in five major European nations.